# Alaw Therapeutics

Source: https://onco.cc/companies/alaw-therapeutics/  
OnCo record `alaw-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alaw Therapeutics makes pills that block CDK2 and CDK4, enzymes that drive cancer cell division, and designs them to reach the brain. Its CDK2 blocker AL-605 began its first human trial in 2026 in breast, ovarian and other cancers with extra copies of the cyclin E1 gene.

## Summary

Alaw Therapeutics is a clinical-stage precision oncology company founded in February 2024 by Torrey Pines and OrbiMed; it is a wholly owned subsidiary of Eilean Therapeutics. It develops highly selective, brain-penetrant small-molecule inhibitors and next-generation targeted degradation approaches, including RIPTAC programmes. On 29 May 2026 it announced first patients dosed in a phase 1a/b trial of AL-605, a selective CDK2 inhibitor, in CCNE1-amplified solid tumours: HR-positive breast cancer that progressed after CDK4/6 inhibitors with CCNE1 amplification or overexpression, and CCNE1-amplified ovarian, endometrial, gastric, oesophageal and triple-negative breast cancers. It also nominated AL-433, a brain-penetrant CDK4 inhibitor designed for selectivity over CDK6, as a development candidate, with first-in-human entry planned for the fourth quarter of 2026 and studies expected to allow patients with active central nervous system tumours or brain metastases. A third programme, AL-273, is a pan-mutant EGFR inhibitor. Nikolay Savchuk is chief executive and John C. Byrd chief medical officer.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.alawtx.com/

## Notes

- Founded in February 2024 per the company's About page. No financing round or amount is disclosed, so no funding row is recorded; OrbiMed is linked because the company names it as a founder and shows it under Investors. Headquarters is from the San Diego dateline of the May 2026 release. Brain penetration and activity in glioblastoma and brain metastasis models are preclinical claims. The ClinicalTrials.gov number for AL-605 was not stated; an Eilean-sponsored first-in-human CDK2 study (NCT07524140, ZE94-0605) may be the same programme, but that was not confirmed.

## Sources

- Official website: https://www.alawtx.com/
- About the company: https://www.alawtx.com/about
- Pipeline milestones release, May 2026: https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HR-positive metastatic breast cancer after CDK4/6 inhibitors](https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [CCNE1](https://onco.cc/targets/ccne1/), [CDK2](https://onco.cc/targets/cdk2/), [CDK4/6](https://onco.cc/targets/cdk4-6/), [EGFR](https://onco.cc/targets/egfr/)
- companies: [OrbiMed](https://onco.cc/companies/orbimed/)

---
JSON: https://onco.cc/api/v1/entities/alaw-therapeutics.json